|Bid||225.00 x 900|
|Ask||244.00 x 900|
|Day's Range||238.60 - 244.45|
|52 Week Range||163.68 - 249.00|
|Beta (5Y Monthly)||1.45|
|PE Ratio (TTM)||54.06|
|Earnings Date||Apr 27, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||266.60|
In a note out Thursday evening, Citi Research analyst Mohit Bansal put his money on (VRTX) the up-and-comer that analysts can’t say enough good things about. “VRTX could be the next entry in the $100B market cap club,” Bansal wrote. (VRTX) (ticker: VRTX) tops Bansal’s ranking of large-cap biotech names, a list that includes (AMGN)(AMGN), (REGN)(REGN), (GILD)(GILD), and (BIIB)(BIIB), among others.
Zacks.com featured highlights include: Chipotle Mexican Grill, Vertex Pharmaceuticals, ResMed, Spirit Airlines and OneMain
Vertex Pharmaceuticals is the IBD Stock Of The Day as shares of the biotech company offer new buying opportunities following the launch of Trikafta in cystic fibrosis treatment.
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ServiceNow posted stronger-than-projected Q4 2019 results on January 29. Analysts have since raised their fiscal 2020 and 2021 earnings estimates for the fast-growing, cloud-focused business services firm...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) just released its latest full-year results and things are looking...
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
During the Lightning Round segment of Mad Money Thursday night one caller asked Jim Cramer about Vertex Pharmaceuticals Inc. : "Wall Street underestimates this stock," said Cramer. In the daily bar chart of VRTX, below, we can see that the stock price turned up strongly from early October when the broad market started its fourth-quarter rally. The daily On-Balance-Volume (OBV) line started its rise in early October and tells us that buyers of VRTX have been more aggressive.
Dow Jones futures fell on coronavirus fears. Amazon stock surged on earnings, leading 3 stocks flashing possible buys. IBM CEO Ginni Rometty is leaving.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
The biotech firm said it has sold $420 million worth of its new cystic fibrosis therapy—five times the amount analysts had anticipated.
Frustrated with the slow pace of drug discovery and desperate to help their loved ones, untrained family members take the work into their own hands by starting biopharma companies. But few such companies have been successful.
Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Late Thursday, Vertex Pharmaceuticals reported adjusted income of $1.70 per share on $1.41 billion in revenue for its fourth quarter ended Dec. 31. As a result, VRTX stock popped.
Vertex Pharmaceuticals Inc. shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates. Vertex shares rose 2.9% after hours, following a 0.9% decline in the regular session to close at $230.31. The company reported fourth-quarter net income of $583.2 million, or $2.23 a share, compared with $1.55 billion, or $5.97 a share, in the year-ago period. Adjusted earnings were $1.70 a share versus $1.30 a share in the year-ago period. Revenue rose to $1.41 billion from $870.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $1.21 a share on revenue of $1.01 billion. Vertex expects "total product" revenue of $5.1 billion to $5.3 billion in 2020, while analysts had forecast on revenue of $4.88 billion.